ProfileGDS5678 / 1432075_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 55% 55% 53% 53% 57% 56% 54% 53% 54% 55% 54% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4755356
GSM967853U87-EV human glioblastoma xenograft - Control 23.3566755
GSM967854U87-EV human glioblastoma xenograft - Control 33.3577155
GSM967855U87-EV human glioblastoma xenograft - Control 43.2313353
GSM967856U87-EV human glioblastoma xenograft - Control 53.2674953
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5469857
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5111856
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.33954
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.290253
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3167354
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3621255
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.288954
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3907455
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3542255